Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL decreased its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,686 shares of the biotechnology company’s stock after selling 234 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Bio-Techne were worth $1,850,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of TECH. UMB Bank n.a. boosted its holdings in shares of Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 168 shares during the period. Brooklyn Investment Group acquired a new position in shares of Bio-Techne during the third quarter valued at $39,000. Quest Partners LLC acquired a new position in shares of Bio-Techne during the third quarter valued at $43,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Bio-Techne by 60.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 253 shares during the period. Finally, Versant Capital Management Inc boosted its holdings in shares of Bio-Techne by 35.0% during the fourth quarter. Versant Capital Management Inc now owns 763 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 198 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TECH. Baird R W downgraded shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. KeyCorp upped their price objective on shares of Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Robert W. Baird downgraded shares of Bio-Techne from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $88.00 to $68.00 in a report on Wednesday, February 19th. Royal Bank of Canada upped their price objective on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a “sector perform” rating in a report on Thursday, February 6th. Finally, Scotiabank upped their price objective on shares of Bio-Techne from $88.00 to $90.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Bio-Techne currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.14.

Insiders Place Their Bets

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the sale, the chief executive officer now owns 39,004 shares in the company, valued at approximately $3,014,619.16. The trade was a 25.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy E. Herr sold 1,860 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the sale, the director now owns 1,976 shares in the company, valued at approximately $130,336.96. The trade was a 48.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.

Bio-Techne Price Performance

Shares of NASDAQ TECH opened at $64.37 on Friday. Bio-Techne Co. has a twelve month low of $58.98 and a twelve month high of $85.57. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $10.18 billion, a price-to-earnings ratio of 65.02, a PEG ratio of 2.88 and a beta of 1.30. The firm has a 50-day moving average of $70.61 and a two-hundred day moving average of $72.67.

Bio-Techne (NASDAQ:TECH) last issued its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. As a group, analysts expect that Bio-Techne Co. will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were issued a dividend of $0.08 per share. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a yield of 0.50%. Bio-Techne’s payout ratio is presently 32.32%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.